Molbio Diagnostics Future CapEx Plan: IPO Proceeds to Fund Automation and Bengaluru R&D Facility
Molbio Diagnostics Limited has outlined its future investment and growth strategy in its September 2026 investor presentation, highlighting continued investment in automation and research & development while maintaining a disciplined approach to manufacturing capacity expansion.
The company, which was listed on the NSE and BSE on August 17, 2026, said deployment of the net proceeds from its recent issue is already underway.
Management indicated that the proceeds are being deployed toward automation and the development of an R&D facility in Bengaluru.
At the same time, Molbio believes its existing manufacturing infrastructure provides sufficient headroom to support growth without requiring significant incremental manufacturing capacity expenditure in the near term.
Molbio’s Near-Term CapEx Strategy
One of the most important messages from management is that Molbio does not currently need major additional manufacturing capacity CapEx.
The company entered FY27 with meaningful capacity headroom.
During FY26, utilization stood at:
- 42% for Truenat devices
- 58% for Truenat test kits
Molbio currently has manufacturing capacity of approximately:
- 39 million Truenat test kits per year
- 5,400 Truenat devices per year
With utilization still well below full capacity, the company believes it can achieve further volume-led growth using its existing manufacturing infrastructure.
Management therefore expects to support growth without near-term incremental capacity CapEx.
IPO Proceeds Being Deployed Into Automation and R&D
While the company does not currently require substantial new manufacturing capacity, it is continuing to invest in areas that can improve future growth.
Management said that following the company’s listing on August 17, 2026, deployment of the net issue proceeds has begun toward:
- Automation
- Building an R&D facility in Bengaluru
The automation investment is expected to support precision, consistency, and manufacturing efficiency, while the Bengaluru R&D facility is intended to strengthen Molbio’s innovation capabilities.
This creates a different CapEx profile from a conventional manufacturing expansion: the company is focusing on technology, automation, and R&D infrastructure rather than immediately adding large amounts of production capacity.
Why Bengaluru R&D Facility Matters
R&D is central to Molbio’s long-term growth strategy.
The company has built a significant internal research organization with:
- 153 R&D professionals
- 136 scientists
- 207 registered patents
- More than 13 years of R&D and product translation experience behind the Truenat platform
Molbio spent ₹87.5 crore on R&D in FY26, compared with ₹68.6 crore in FY25 and ₹59.8 crore in FY24.
This represents a 46% increase in annual R&D spending compared with FY24.
The planned Bengaluru R&D facility should therefore be viewed in the context of Molbio’s strategy to continue developing new diagnostic products and platforms.
34 Assays in the Pipeline
Molbio is not relying only on its existing test portfolio to generate future growth.
The company currently has 34 additional assays in its pipeline covering 22 diseases.
Its development strategy extends beyond infectious diseases into areas such as:
- Oncology
- Women’s health
- Non-communicable diseases
- Antimicrobial resistance
- Other diagnostic applications
The company is also looking at developing new point-of-care platforms using advanced multiplex PCR technologies.
A larger assay portfolio could increase the utilization of Molbio’s existing Truenat installed base because customers can potentially conduct more types of tests using the platform.
Test Kits Are the Key Recurring Revenue Driver
Molbio’s business model has an important recurring component through its Truenat test kits.
The company had more than 12,500 Truenat devices installed across 90+ countries as of FY26.
Test-kit consumption has grown strongly, increasing from 8.8 million units in FY24 to 17.56 million units in FY26, representing approximately 41% CAGR over the period.
Test kits accounted for approximately 74% of product revenue in FY26.
This is important because every expansion in the installed base of Truenat devices can potentially create a larger recurring opportunity for consumable test-kit sales.
Management Expects Volume-Led Growth
Management believes the combination of existing capacity headroom and increasing test-kit consumption can support growth without immediate large-scale manufacturing expansion.
The company said:
“We entered FY 27 with meaningful capacity headroom.”
The strategy is therefore to increase utilization of existing assets rather than immediately build substantial new manufacturing facilities.
This could potentially allow Molbio to generate operating leverage as volumes increase, although actual margins will depend on product mix, pricing, international investments, and other operating costs.
Q1 FY27 Shows Strong Operating Leverage
Molbio reported a significant improvement in its Q1 FY27 financial performance.
Total income increased to approximately ₹411.5 crore, compared with ₹100.5 crore in Q1 FY26.
EBITDA stood at approximately ₹103.7 crore, compared with an EBITDA loss of ₹14.5 crore in the year-ago quarter.
EBITDA margin improved to 25.2% from negative 14.4%.
Profit after tax stood at approximately ₹52.7 crore, compared with a loss of ₹23.9 crore in Q1 FY26.
Management attributed the strong performance primarily to higher Truenat test-kit consumption.
The company also cautioned that its revenue profile remains non-linear, meaning quarterly performance can vary significantly, and management believes the business should be evaluated on a full-year basis.
₹57 Crore of Export Orders Deferred From Q4 FY26
An important point in the management commentary concerns approximately ₹57 crore of export orders that were originally related to Q4 FY26.
These orders were deferred because of the prevailing situation in the Gulf and were subsequently recognized in Q1 FY27.
Therefore, investors should consider this timing factor when comparing quarterly results.
The company has specifically highlighted the non-linear nature of its revenue profile, making full-year performance more meaningful than simply extrapolating one quarter.
International Expansion Remains a Key Growth Driver
Molbio is also increasing its international focus.
The company is deepening its presence in:
- Africa
- Southeast Asia
It is also entering Latin America and progressing regulatory approvals in developed markets.
The company is pursuing regulatory pathways including CE-IVDR for its Truenat CT/NG test.
International expansion could provide another avenue for increasing utilization of the existing manufacturing base before significant additional capacity investment becomes necessary.
Strategic Acquisitions to Complement Organic Growth
Molbio is also pursuing an inorganic growth strategy.
Management says the company intends to use strategic acquisitions and alliances to expand capabilities and product offerings.
The acquisition of Prognosys Medical Systems has already expanded Molbio’s presence into radiology imaging.
The company also has exposure to digital pathology through its investment in OptraSCAN.
This strategy allows Molbio to diversify beyond its core molecular diagnostics platform while building a broader healthcare diagnostics portfolio.
Future Growth Strategy
Molbio’s investor presentation identifies several key pillars for future growth.
Expand the Truenat Test Menu
The company plans to commercialize additional assays and increase the utility of its installed Truenat base.
Develop New Point-of-Care Platforms
Molbio plans to use its R&D capabilities and multiplex PCR technologies to develop platforms addressing additional diagnostic needs.
Expand Internationally
Africa, Southeast Asia and Latin America are important areas of international expansion, while the company is also pursuing regulatory approvals in developed markets.
Increase Automation
Automation is one of the immediate areas where IPO proceeds are being deployed.
Strengthen R&D
The Bengaluru R&D facility is expected to support future innovation and product development.
Pursue Strategic Acquisitions
The company intends to supplement organic growth through acquisitions and alliances.
What Does This Mean for Investors?
The most important takeaway is that Molbio currently has manufacturing capacity headroom.
With Truenat test-kit utilization at only 58% and device utilization at 42% in FY26, the company believes it can increase volumes without immediately undertaking another major manufacturing capacity expansion.
This can be strategically important because future revenue growth can potentially come from better utilization of existing assets.
At the same time, Molbio is not reducing investment in growth. Instead, it is directing capital toward automation, R&D infrastructure, and product innovation.
The company’s growing assay pipeline and expanding international footprint could increase demand for its existing Truenat platform.
Key Risks and Points to Monitor
Investors should also monitor several factors.
Quarterly volatility:
Management has cautioned that Molbio’s revenue profile is non-linear, so quarterly results can fluctuate.
International execution:
Expansion into new international markets depends on regulatory approvals, distribution, and customer adoption.
R&D execution:
The commercial success of the 34 assays in the pipeline will depend on development, validation, regulatory approval, and market adoption.
Acquisition integration:
The company’s inorganic expansion strategy introduces execution and integration risks.
Capacity utilization:
The investment thesis depends partly on increasing utilization of existing manufacturing capacity.
Cash-flow quality:
Management has specifically said it remains focused on improving cash-flow quality as international and acquired businesses scale.
Molbio Diagnostics CapEx and Growth Plan: Key Takeaways
- Molbio entered FY27 with substantial manufacturing capacity headroom.
- FY26 Truenat device utilization was 42%.
- FY26 Truenat test-kit utilization was 58%.
- Existing capacity is approximately 39 million test kits and 5,400 devices annually.
- Management does not expect near-term incremental manufacturing capacity CapEx.
- IPO proceeds are being deployed toward automation and a Bengaluru R&D facility.
- FY26 R&D expenditure reached ₹87.5 crore.
- The company has 34 assays covering 22 diseases in its pipeline.
- More than 12,500 Truenat devices are installed across 90+ countries.
- Test-kit volumes grew at approximately 41% CAGR during FY24-FY26.
- Test kits contributed approximately 74% of product revenue in FY26.
- International expansion remains a major growth priority.
- Strategic acquisitions and alliances are part of the company’s growth strategy.
Bottom Line
Molbio Diagnostics’ September 2026 investor presentation provides a relatively clear picture of its future investment strategy.
Rather than immediately committing large amounts of capital to new manufacturing capacity, the company intends to use its existing capacity more efficiently while investing in automation, R&D and new diagnostic products.
The planned Bengaluru R&D facility, increasing R&D expenditure and 34-assay pipeline indicate that Molbio is positioning itself for expansion beyond its existing infectious-disease portfolio.
For investors, the combination of low current capacity utilization, a growing recurring test-kit business, international expansion and continued R&D investment is an important part of the company’s longer-term growth story.
The key question going forward will be whether Molbio can convert its existing capacity headroom and R&D pipeline into sustained test-kit volume growth, international revenues and stronger cash generation.